[1]Gerlach AT, Dasta JF. Dexmedetomidine: an updated review[J]. Ann Pharmacother, 2007, 41(2): 245-252.
[2]舒成仁,黄露,葛苗苗,等. 盐酸右美托咪定在健康人体的药动学[J]. 医药导报,2011,30(12): 1555-1558.
[3]Ryu JH, Lee SW, Lee JH, et al. Randomized double-blind study of remifentanil and dexmedetomidine for flexible bronchoscopy [J]. Br J Anaesth, 2012, 108(3): 503-511.
[4]Holliday SF, Kane-Gill SL, Empey PE, et al. Interpatient variability in dexmedetomidine response: a survey of the literature[J]. Sci World J, 2014, 2014(1): 805013.
[5]Vilo S, Rautiainen P, Kaisti K, et al. Pharmacokinetics of intravenous dexmedetomidine in children under 11 yr of age[J]. Br J Anaesth, 2008, 100(5): 697.
[6]Weerink MAS, Struys MMRF, Hannivoort LN, et al. Clinical pharmacokinetics and pharmacodynamics of dexmedetomidine[J]. Clin Pharmacokinet, 2017, 56(8): 893-913.
[7]Precedex product label. Hospira, Inc., Lake Forest, IL 60045 USA; 2016.
[8]Oscarson ML,McLellan RA,Gullstén H,et al.Characterisation and PCR-based detection of a CYP2A6 gene deletion found at a high frequency in a Chinese population[J].FEBS Lett,1999,448(1):105-110.
[9]方艳. 人肝微粒体CYP2A6和CYP2C9基因多态性对其药物代谢活性的影响[D]. 郑州大学硕士学位论文,2014.
[10]Iirola T,Aantaa R,Laitio R,et al.Pharmacokinetics of prolonged infusion of high-dose dexmedetomidine in critically ill patients[J].Crit Care, 2011,15(5):R257.
[11]Vlitalo PA, Ahtola-Stil T, Wighton A, et al. Population pharmacokinetics of dexmedetomidine in critically ill patients [J]. Clin Drug Investig, 2013, 33(8): 579-587.
[12]Wiczling P, Bartkowska-Sniatkowska A, Szerkus O, et al. The pharmacokinetics of dexmedetomidine during long-term infusion in critically ill pediatric patients. A Bayesian approach with informative priors [J]. J Pharmacokinet Pharmacodyn, 2016, 43(3): 315-324.
[13]Su F, Nicolson SC, Gastonguay MR, et al. Population pharmacokinetics of dexmedetomidine in infants after open heart surgery[J]. Anesth Analg, 2010, 110(5): 1383-1392.
[14]Li A, Yuen VM, Goulay-Dufay S, et al. Pharmacokinetic and pharmacodynamic study of intranasal and intravenous dexmedetomidine[J]. Br J Anaesth, 2018, 120(5): 960-968.
[15]Zhang T, Deng Y, He P, et al. Effects of mild hypoalbuminemia on the pharmacokinetics and pharmacodynamics of dexmedetomidine in patients after major abdominal or thoracic surgery [J]. J Clin Anesth, 2015, 27(8): 632-637.
[16]Anttila M, Penttila J, Helminen A, et al. Bioavailability of dexmedetomidine after extravascular doses in healthy subjects [J]. Br J Clin Pharmacol, 2003, 56(6): 691-693.
[17]Yoo H, Iirola T, Vilo S, et al. Mechanism-based population pharmacokinetic and pharmacodynamic modeling of intravenous and intranasal dexmedetomidine in healthy subjects [J]. Eur J Clin Pharmacol, 2015, 71(10): 1197-1207.
[18]De Wolf AM, Fragen RJ, Avram MJ, et al. The pharmacokinetics of dexmedetomidine in volunteers with severe renal impairment [J]. Anesth Analg. 2001, 93(5): 1205-1209.
[19]Lee S, Kim BH, Lim K, et al. Pharmacokinetics and pharmacodynamics of intravenous dexmedetomidine in healthy Korean subjects [J]. J Clin Pharma Therap, 2012, 37(6): 698-703.
[20]Karol MD, Maze M. Pharmacokinetics and interaction pharmacodynamics of dexmedetomidine in humans [J]. Best Prac Res Clin Anaesthesiol, 2000, 14(2): 261-269.
[21]Kivisto KT,Kallio A,Neuvonen PJ.Pharmacokinetics and pharmacodynamics of transdermal dexmedetomidine[J].Eur J Clin Pharmacol,1994,46(4):345-349.
[22]Dyck JB, Maze M, Haack C, et al. The pharmacokinetics and hemodynamic effects of intravenous and intramuscular dexmedetomidine hydrochloride in adult human volunteers [J]. Anesthesiology, 1993, 78(5): 813-820.
[23]Dutta S, Lal R, Karol MD, et al. Influence of cardiac output on dexmedetomidine pharmacokinetics [J]. J Pharm Sci, 2000, 89(4): 519-527.
[24]Rowland M, Tozer TN. Clinical pharmacokinetics: concepts and applications [M]. Baltimore: Williams & Wilkins, 1995.
[25]He W, Zhang S, Song A, et al. Greater abdominal fat accumulation is associated with higher metabolic risk in Chinese than in white people: an ethnicity study [J]. PLoS One, 2013, 8(3): e58688.
[26]Pirisi A. Nicotine metabolism varies between different ethnic groups [J]. Lancet, 2002, 359(9302): 234.
[27]Portmann S, Kwan HY, Theurillat R, et al. Enantioselective capillary electrophoresis for identification and characterization of human cytochrome P450 enzymes which metabolize ketamine and norketamine in vitro[J]. J Chromatogr A, 2010, 1217(51): 7942-7948.
[28]Kaivosaari S, Toivonen P, Aitio O, et al. Regio-and stereospecific N-glucuronidation of medetomidine: the differences between UDP glucuronosyltransferase (UGT) 1A4 and UGT2B10 account for the complex kinetics of human liver microsomes[J]. Drug Metab Dispos, 2008, 36(8): 1529-1537. |